Telix Pharmaceuticals reports receipt of $11.4M Refundable R&D Tax Offset

July 27th, 2020 reform R&D Tax Incentive

Melbourne based Telix Pharmaceuticals Ltd has reported during the week receipt of a $11.4M Refundable R&D Tax Offset in respect of activity conducted during the YE 31 December 2019.
This would be one of the largest single year Refundable offset receipts in the history of the R&D Tax Incentive, and infers an R&D Expenditure of approximately $26M AUD.
The underlying activity relates to development of diagnostic and therapeutic products using molecularly targeted radiation.
Receipt of a tax offset of this magnitude reduces the need for a company to raise additional capital to complete trials, and could make pathway to commercialisation exponentially easier.

Post a Comment

(*) indicates required field.